menu
    • menu
    [{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Autologous regenerative epidermal cells","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Not Applicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Regenerative Epidermal Suspension","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avita Medical \/ Not Applicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Regenerative Epidermal Suspension","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avita Medical \/ Not Applicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Regenerative Epidermal Cell","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Avita Medical

    Menu

    Avita Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avita Medical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avita Medical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Regenerative Epidermal Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® S...

                            Details : The RECELL® System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells.

                            Brand Name : RECELL

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 09, 2022

                            Lead Product(s) : Regenerative Epidermal Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avita Medical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avita Medical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Regenerative Epidermal Suspension

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruct...

                            Details : Enrollment of Pivotal trial for Recell (Regenerative Epidermal Suspension) is completed and topline result are expecting in the second half of 2022 for treatment of soft-tissue reconstruction.

                            Brand Name : Recell

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 06, 2022

                            Lead Product(s) : Regenerative Epidermal Suspension

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avita Medical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avita Medical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Regenerative Epidermal Suspension

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical’s Pivotal Study of the RECELL® System f...

                            Details : The primary effectiveness evaluation is based on a comparison of the incidence of successful repigmentation with RECELL versus that of a standard of care control. Long-term durability data (assessing sustained repigmentation over 52 weeks) will be collec...

                            Brand Name : Recell

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 16, 2021

                            Lead Product(s) : Regenerative Epidermal Suspension

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Avita Medical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avita Medical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous regenerative epidermal cells

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL® System for Pediatric Scald Injur...

                            Details : This study seeks to demonstrate that treatment with the RECELL System of partial-thickness burn injuries within 72-hours can safely increase the healing at day 10.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 04, 2020

                            Lead Product(s) : Autologous regenerative epidermal cells

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth